Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

    ... Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with ... The study cohort consisted of patients with new-onset transfusion dependence (TD). All patients received an ESA at least once during ...

    Research Article last updated 05/26/2015 - 11:49am.

  2. Blood stream infection after stem cell transplantation in children with idiopathic aplastic anemia

    Journal Title:  Biol Blood Marrow Transplant Primary Author:  ... transplantation from unrelated donors, frequent blood transfusion before transplantation, major or major+minor mismatch of ABO ...

    Research Article last updated 04/23/2014 - 10:34am.

  3. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?

    ... Erythropoiesis-stimulating agents (ESA) may reduce red blood cell transfusion requirements. MDS patients receiving ESA were reviewed for ...

    Research Article last updated 12/09/2015 - 8:52am.

  4. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    Journal Title:  Blood Primary Author:  Peffault ... six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by CH50 ≤10% of ...

    Research Article last updated 01/20/2015 - 2:28pm.

  5. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q ... that lenalidomide is effective not only in reducing red blood cell (RBC) transfusion burden, but also in modifying the disease ...

    Research Article last updated 12/08/2015 - 1:06pm.

  6. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

    ... with reduced overall survival were increasing age, transfusion dependency (defined as having received at least one red blood cell transfusion every 8 weeks over a period of 4 months), Eastern ...

    Research Article last updated 11/10/2015 - 10:47am.

  7. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

    ... Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and ... achieved long-term packed red blood cell PRBC transfusion independence , and all PRCA responders achieved long-term ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk ... of these patients had an ongoing requirement for red blood cell transfusions despite previous treatment with recombinant ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    Journal Title:  Blood Primary Author:  Itzykson ... , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) independently ...

    Research Article last updated 07/28/2014 - 8:53am.

  10. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... patients reached HI-E (p=0.07); 48% and 20% achieved transfusion independence (p=0.01). Median OS was 19.6months in the ESA and ... and duration, and of our proposed azacitidine risk score (Blood 2011;117:403-11). Adding an ESA to azacitidine in higher-risk MDS should ...

    Research Article last updated 07/28/2014 - 9:30am.